Diabetic retinopathy. Diabetes mellitus due to underlying condition with ophthalmic complications
Conditions
Interventions
Intervention 1: Intervention group: Intervention group will receive a capsule containing curcumin-piperine in the amount of 500 mg of curcumin and 5 mg of piperine twice a day after breakfast and in t
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age 30 to 65 years Diagnosis of diabetic retinopathy with the approval of an ophthalmologist, imaging, CT scan or PCR Definitive diagnosis of diabetes by a diabetic doctor (fasting blood sugar above 126 mg / dL measured twice or HbA1C greater than or equal to 6/5%)
Exclusion criteria
Exclusion criteria: Sensitivity to plant products such as turmeric and pepper Follow a special diet in the last 3 months Taking anticoagulants such as heparin, warfarin, aspirin, etc. Pregnancy and lactation Patient dissatisfaction Taking herbal medicines or supplements in the last 3 months Requires the use of anti-VEGF (Anti–vascular endothelial growth factor) Use of therapies including laser therapy, surgery and intraocular injections Having certain diseases such as congenital diseases, type 1 diabetes, immune deficiency, cancer Uncontrolled diabetes Consume less than 80% of the curcumin piperine supplement Report any adverse side effects after taking supplements If other treatments of the patient such as treatment of hypertension, hyperlipidemia, etc. are variable during the course of treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Macular artery density. Timepoint: At baseline and end of the study. Method of measurement: OCTA (Optical Coherence Tomography angiography) device.;C reactive Protein (CRP). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Superoxide dismutase. Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit.;Total antioxidant capacity. Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit.;Fasting blood sugar. Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Triglycerides. Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Malondialdehyde. Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood urea nitrogen (BUN). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Creatinine (Cr). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Sleep Quality. Timepoint: At baseline and end of the study. Method of measurement: Pittsburgh sleep quality index (PSQI) questionnaire.;Emotional status (stress, anxiety, and depression). Timepoint: At baseline and end of the study. Method of measurement: DASS-21 questionnaire.;Weight. Timepoint: At baseline and end of the study. Method of measurement: Digital Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Bagherniya
Esfahan University of Medical Sciences
Outcome results
None listed